Biliary Tract Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Cholangiocarcinoma (219)

Gallbladder Cancer (45)

Cholangiocarcinoma (219)

Gallbladder Cancer (45)

›

FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
MSI-H/dMMR	Biliary Tract Cancer	MSI-H/dMMR	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
IDH1 R132	Cholangiocarcinoma	IDH1 R132	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
FGFR2 fusion	Biliary Tract Cancer	FGFR2 fusion	Biliary Tract Cancer	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
HER-2 negative + PD-L1 expression	Biliary Tract Cancer	HER-2 negative + PD-L1 expression	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2	cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2

Biliary Tract Cancer

Associations(390)

Associations
(390)